Clinical Trials Sponsored by FutureGen Biopharmaceutical (Beijing) Co., Ltd

Total 1112 results

FutureGen Biopharmaceutical (Beijing) Co., Ltd

Recruiting

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Locally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

China
FutureGen Biopharmaceutical (Beijing) Co., Ltd

Recruiting

Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

Advanced Unresectable Solid Tumors

China
Beijing QL Biopharmaceutical Co.,Ltd

Enrolling by invitation

A Study of ZT002 Injection in Participants With Overweight or Obesity

Overweight or Obesity

China
Beijing Kanova Biopharmaceutical Co., LTD

Active, not recruiting

Phase I of XKH001Injection in Healthy Adults

Healthy Adults

China
Beijing Kanova Biopharmaceutical Co., LTD

Not yet recruiting

XKH001 Injection in Healthy Subjects

Asthma
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

A Study of STSA-1201 in Healthy Subjects

Healthy

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Healthy

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Unknown

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

Healthy Subject

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Healthy

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Antineutrophil Cytoplasmic Antibody Associated Vasculitis

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

Primary Immune Thrombocytopenia

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

ANCA-associated Vasculitis

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

A Study of STSA-1002 in Healthy Subjects

Healthy Subject

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd

Active, not recruiting

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

COVID-19 Pneumonia

Spain, Bangladesh, China, India, Indonesia
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd

Completed

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

COVID-19

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrei Biotechnology Co.,Ltd

Completed

Safety and Tolerability of BDB-001 Injection in Healthy Subjects

Healthy

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrei Biotechnology Co.,Ltd

Completed

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

Healthy

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23

Healthy Volunteers

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months

Meningitis, Meningococcal

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months

Healthy Population

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Completed

Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above

Pneumonia, Pneumococcal

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Recruiting

Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine

Healthy Volunteers

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Not yet recruiting

Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers

Pneumonia, Pneumococcal

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old

Healthy Volunteers

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Completed

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months

Meningitis, Meningococcal

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Completed

Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Dysentery, Bacillary | Dysentery

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Recruiting

Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants

Healthy Volunteers

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Recruiting

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

Healthy Volunteers

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Recruiting

Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years

Shigellosis | Dysentery

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years

Healthy Population

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Completed

Immunogenicity and Safety of Enterovirus Type 71 Vaccine,Inactivated(Vero Cells) in Volunteers Aged From 6 to 71 Months

Healthy Volunteers

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Completed

Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old

Dysentery, Bacillary | Dysentery

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Novikang Medical Technology Co., LTD

Completed

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Hemophilia

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Sanuo Jiayi Biotechnology Co. LTD

Terminated

To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Chronic Hepatitis b

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Sanuo Jiayi Biotechnology Co. LTD

Terminated

Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Chronic Hepatitis b

China
Beijing Kanghong Biopharmaceutical Co., Ltd.

Not yet recruiting

Phase 1 Trial of KH801

Advanced Solid Tumors

China
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Beijing 302 Hospital

Unknown

Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Advanced Liver Cancer

China
Beijing Kejing Biotechnology Co., Ltd.
Beijing Kejing Biotechnology Corp.

Withdrawn

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients (CCT-ANK-11)

Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)

China
Binhui Biopharmaceutical Co., Ltd.

Not yet recruiting

OH2 Administered by Intratumoral Injection

Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZB-0004 in Patients With Solid Tumors

NSCLC | Advanced Solid Tumor

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM602 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

AML | MDS

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer

Advanced Liver Cancer

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

Advanced Colorectal Carcinoma

China

Clinical Trials Sponsored by FutureGen Biopharmaceutical (Beijing) Co., Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations